SynclearON is being built by four co-founders united by a shared mission: to develop transformative therapies for Parkinson’s disease. Combining expertise in neuroscience, drug discovery, translational research, and biotechnology entrepreneurship, we are advancing a novel disease-modifying approach with the potential to slow down or halt disease progression.
Interested in learning more about SynclearON or exploring collaboration opportunities? We'd love to hear from you.
founders[at]synclearon.com



